Advanced search
Publication Cover
International Journal of Nanomedicine Volume 14, 2019 - Issue
Submit an article Journal homepage
131
Views
8
CrossRef citations to date
0
Altmetric
Original Research

RGDV-modified gemcitabine: a nano-medicine capable of prolonging half-life, overcoming resistance and eliminating bone marrow toxicity of gemcitabine

Wenchao Liu1 Beijing Area Major Laboratory of Peptide and Small Molecular Drugs, Department of Medicinal Chemistry, School of Pharmaceutical Sciences, Capital Medical University, Beijing100069, People’s Republic of China;2 Engineering Research Center of Endogenous Prophylactic of Ministry of Education of China, Department of Medicinal Chemistry, School of Pharmaceutical Sciences, Capital Medical University, Beijing100069, People’s Republic of China
,
Yujia Mao1 Beijing Area Major Laboratory of Peptide and Small Molecular Drugs, Department of Medicinal Chemistry, School of Pharmaceutical Sciences, Capital Medical University, Beijing100069, People’s Republic of China;2 Engineering Research Center of Endogenous Prophylactic of Ministry of Education of China, Department of Medicinal Chemistry, School of Pharmaceutical Sciences, Capital Medical University, Beijing100069, People’s Republic of China
,
Xiaoyi Zhang1 Beijing Area Major Laboratory of Peptide and Small Molecular Drugs, Department of Medicinal Chemistry, School of Pharmaceutical Sciences, Capital Medical University, Beijing100069, People’s Republic of China;2 Engineering Research Center of Endogenous Prophylactic of Ministry of Education of China, Department of Medicinal Chemistry, School of Pharmaceutical Sciences, Capital Medical University, Beijing100069, People’s Republic of China
,
Yaonan Wang1 Beijing Area Major Laboratory of Peptide and Small Molecular Drugs, Department of Medicinal Chemistry, School of Pharmaceutical Sciences, Capital Medical University, Beijing100069, People’s Republic of China;2 Engineering Research Center of Endogenous Prophylactic of Ministry of Education of China, Department of Medicinal Chemistry, School of Pharmaceutical Sciences, Capital Medical University, Beijing100069, People’s Republic of China
,
Jianhui Wu1 Beijing Area Major Laboratory of Peptide and Small Molecular Drugs, Department of Medicinal Chemistry, School of Pharmaceutical Sciences, Capital Medical University, Beijing100069, People’s Republic of China;2 Engineering Research Center of Endogenous Prophylactic of Ministry of Education of China, Department of Medicinal Chemistry, School of Pharmaceutical Sciences, Capital Medical University, Beijing100069, People’s Republic of ChinaORCID Iconhttps://orcid.org/0000-0001-9416-8952
ORCID Icon,
Shurui Zhao1 Beijing Area Major Laboratory of Peptide and Small Molecular Drugs, Department of Medicinal Chemistry, School of Pharmaceutical Sciences, Capital Medical University, Beijing100069, People’s Republic of China;2 Engineering Research Center of Endogenous Prophylactic of Ministry of Education of China, Department of Medicinal Chemistry, School of Pharmaceutical Sciences, Capital Medical University, Beijing100069, People’s Republic of China
,
Shiqi Peng1 Beijing Area Major Laboratory of Peptide and Small Molecular Drugs, Department of Medicinal Chemistry, School of Pharmaceutical Sciences, Capital Medical University, Beijing100069, People’s Republic of China;2 Engineering Research Center of Endogenous Prophylactic of Ministry of Education of China, Department of Medicinal Chemistry, School of Pharmaceutical Sciences, Capital Medical University, Beijing100069, People’s Republic of ChinaORCID Iconhttps://orcid.org/0000-0003-2669-6715
ORCID Icon &
Ming Zhao1 Beijing Area Major Laboratory of Peptide and Small Molecular Drugs, Department of Medicinal Chemistry, School of Pharmaceutical Sciences, Capital Medical University, Beijing100069, People’s Republic of China;2 Engineering Research Center of Endogenous Prophylactic of Ministry of Education of China, Department of Medicinal Chemistry, School of Pharmaceutical Sciences, Capital Medical University, Beijing100069, People’s Republic of China;3 Department of Biomaterials, Beijing Laboratory of Biomedical Materials and Key Laboratory of Biomedical Materials of Natural Macromolecules, Beijing University of Chemical Technology, Beijing100026, People’s Republic of ChinaCorrespondence[email protected]
 show all
Pages 7263-7279 | Published online: 06 Sep 2019

Citations (8)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (1)

Guanyu Li, Tong Wang, Xiaoyi Zhang, Shurui Zhao, Yaonan Wang, Jianhui Wu, Shiqi Peng & Ming Zhao. (2020) Development of 13-Cys-BBR as an Agent Having Dual Action of Anti-Thrombosis and Anti-Inflammation. Drug Design, Development and Therapy 14, pages 2187-2197.
Read now

Articles from other publishers (7)

Tao Sun & Chen Jiang. (2023) Stimuli-responsive drug delivery systems triggered by intracellular or subcellular microenvironments. Advanced Drug Delivery Reviews 196, pages 114773.
Crossref
Jianjun Qi, Zihua Zeng, Zhenghu Chen, Cole Nipper, Xiaohui Liu, Quanyuan Wan, Jian Chen, Ching-Hsuan Tung & Youli Zu. (2022) Aptamer–Gemcitabine Conjugates with Enzymatically Cleavable Linker for Targeted Delivery and Intracellular Drug Release in Cancer Cells. Pharmaceuticals 15:5, pages 558.
Crossref
Feifei Cheng, Xuejuan Wang, Yi-Shiou Chiou, Chuyu He, Hui Guo, Yan Qin Tan, Basappa Basappa, Tao Zhu, Vijay Pandey & Peter E. Lobie. (2022) Trefoil factor 3 promotes pancreatic carcinoma progression via WNT pathway activation mediated by enhanced WNT ligand expression. Cell Death & Disease 13:3.
Crossref
Mariana Pereira & Nuno Vale. (2022) Two Possible Strategies for Drug Modification of Gemcitabine and Future Contributions to Personalized Medicine. Molecules 27:1, pages 291.
Crossref
Sisi Yi, Chen Feng & Xiaohua Hu. (2021) Gemcitabine Nanoparticles Improve the Activity of Ovarian Cancer Cells by Inhibiting CA-125 and Apoptosis-Related Proteins. Journal of Biomaterials and Tissue Engineering 11:7, pages 1400-1405.
Crossref
Aleksandra Hawryłkiewicz & Natalia Ptaszyńska. (2021) Gemcitabine Peptide-Based Conjugates and Their Application in Targeted Tumor Therapy. Molecules 26:2, pages 364.
Crossref
Xiaoyi Zhang, Jinhuan Zhang, Wenchao Liu, Yaonan Wang, Jianhui Wu, Shurui Zhao, Ming Zhao & Shiqi Peng. (2020) Exploring the action of RGDV-gemcitabine on tumor metastasis, tumor growth and possible action pathway. Scientific Reports 10:1.
Crossref

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.